AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC

被引：0
|
作者：
Besse, B. [1 ]
Felip, E. [2 ]
Kim, E. S. [3 ]
Clifford, C. [4 ]
Louie-Gao, M. [4 ]
Yagui-Beltran, A. [4 ]
Popat, S. [5 ]
机构：
[1] Inst Gustave Roussy, Dept Med, Villjuif, France
[2] Vall DHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[3] Atrium Hlth, Levine Canc Inst, Dept Solid Tumor Oncol, Charlotte, NC USA
[4] Blueprint Med Corp, Cambridge, MA USA
[5] Royal Marsden Hosp, Dept Med, Lung Canc Unit, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
tyrosine kinase inhibitor; clinical trial; RET;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P87.02
引用
收藏
页码：S684 / S684
页数：1
相关论文
共 50 条
  • [1] AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC
    Besse, B.
    Felip, E.
    Kim, E. S.
    Clifford, C.
    Louie-Gao, M.
    Yagui-Beltran, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S44 - S45
  • [2] AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).
    Besse, Benjamin
    Felip, Enriqueta
    Clifford, Corinne
    Louie-Gao, Melinda
    Green, Jennifer
    Turner, Christopher D.
    Popat, Sanjay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion-positive advanced/metastatic NSCLC.
    Popat, Sanjay
    Felip, Enriqueta
    Kim, Edward S.
    de Marinis, Filippo
    Cho, Byoung Chul
    Wermke, Martin
    De langen, Adrianus
    Ferrara, Roberto
    Kanzler, Stephan
    Cecere, Fabiana Letizia
    Galetta, Domenico
    Lee, Dae Ho
    Gregorc, Vanesa
    Rodrigues, Ana
    Britschgi, Christian
    Rahman, Ahmadur
    Ndunda, Diana
    Noe, Johannes
    Lu, Danny
    Besse, Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] RET plus advanced NSCLC RET Inhibitor approved for First-line Use
    Freye, Reimund
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 73 - 73
  • [5] RET plus advanced NSCLC RET Inhibitor approved for First-Line Use
    Freye, Reimund
    [J]. ACTA HAEMATOLOGICA, 2022, 145 (02) : 232 - 232
  • [6] NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
    de Castro Jr, Gilberto
    Rizvi, Naiyer A.
    Schmid, Peter
    Syrigos, Konstantinos
    Martin, Claudio
    Yamamoto, Nobuyuki
    Cheng, Ying
    Moiseyenko, Vladimir
    Summers, Yvonne
    Vynnychenko, Ihor
    Lee, Sung Yong
    Bryl, Maciej
    Zer, Alona
    Erman, Mustafa
    Timcheva, Constanta
    Raja, Rajiv
    Naicker, Kirsha
    Scheuring, Urban
    Walker, Jill
    Mann, Helen
    Chand, Vikram
    Mok, Tony
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 106 - 119
  • [7] Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
    An, Li
    Chen, Pengzhi
    Wang, Junfeng
    Qin, Xuebing
    Liu, Tingting
    Gao, Yanhong
    Wang, Peng
    Zhang, Dong
    Fang, Xiangqun
    Zhang, Zhijian
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
    Mok, Tony
    Schmid, Peter
    De Castro, Gilberto, Jr.
    Syrigos, Kostas
    Martin, Claudio
    Yamamoto, Nobuyuki
    Aren, Osvaldo
    Arrieta, Oscar
    Gottfried, Maya
    Jazieh, Abdul Rahman
    Ramlau, Rodryg
    Timcheva, Constanta
    Trani, Leonardo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1084 - S1084
  • [9] Durvalumab ± Tremelimumab plus Chemotherapy as First-line Therapy for metastatic NSCLC: Results of the Phase 3 POSEIDON Study
    Rawluk, J.
    Johnson, M. L.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Vasiliev, A.
    Kim, S. -W
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. -T
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Shi, X.
    Poole, L.
    Medic, N.
    Peters, S.
    Garon, E.
    Mok, T. S. K.
    Thomas, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 102 - 103
  • [10] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
12345